Gary Gize, MD

Articles by Gary Gize, MD

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

ByKathy D. Miller, MD,Judy Sisk, RN,Rafat Ansari, MD,Gary Gize, MD,Sreenivasa Nattam, MD,Kenneth Pennington, MD,George W. Sledge, Jr, MD

February 1st 2001

A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing

Latest Updated Articles

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer
Published: February 1st 2001 | Updated:

Gary Gize, MD

Articles by Gary Gize, MD

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

Latest Updated Articles

Trending on CancerNetwork

How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap

Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer

Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL

Sac-TMT Combo Produces Encouraging Activity in Pretreated Metastatic CRPC

Short-Course Radiation May Be Feasible in Older Rectal Cancer Population